Determination of Amigo2 targeting preventive agents for liver metastasis

2019 Fiscal Year Final Research Report

• Project/Area Number: 18K15125
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: National Cancer Center Japan
• Principal Investigator: Kanda Yusuke 国立研究開発法人国立がん研究センター, 研究所, 特任研究員(シニア・リサーチフェロー) (80803949)
• Project Period (FY): 2018-04-01 – 2020-03-31
• Keywords: 肝転移予防 / Amigo2

Outline of Final Research Achievements

Development of preventive drugs for metastasis is expected to improve the prognosis of cancer patients. Previously, we identified Amigo2 as a driver gene involved in liver metastasis. Based on the idea that the signaling pathway-inhibitors required for Amigo2 expression may prevent liver metastasis, we evaluated the preventive effect of six kinds of Amigo2 inhibitors, which were found in our previous study, on liver metastasis. Each inhibitor decreased the metastasis. These results suggest that signaling molecule inhibitors, which decrease Amigo2 expression, could prevent liver metastasis.

Free Research Field

がん転移

Academic Significance and Societal Importance of the Research Achievements

肝転移予防薬の開発は、がん患者の予後を改善する上で重要な課題である。本研究で得られた成果は、Amigo2発現を抑制する複数種類のシグナル分子阻害剤が肝転移を抑制することを見出したものであり、既に承認済みの分子標的薬を活用したドラッグリポジショニングによる臨床応用への展開が期待される。